Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
HOUSTON - Kamada Ltd. (NASDAQ:KMDA; TASE:KMDA.TA), a biopharmaceutical company with a market capitalization of $416 million and annual revenues of $167 million, announced Monday that the U.S. Food and Drug Administration has approved the supplement to its existing Biologics License Application for the company’s plasma collection center in Houston, Texas, clearing the facility to begin commercial sales of normal source plasma. According to InvestingPro data, the company has demonstrated strong financial health with an impressive 11.8% revenue growth over the last twelve months.
The 12,000-square-foot Houston facility supports 50 donor beds with a planned capacity of approximately 50,000 liters per year. According to the company’s press release, the center is expected to generate annual revenues of $8 million to $10 million in sales of normal source plasma at full capacity, representing a potential 5-6% increase to the company’s current revenue base. InvestingPro subscribers can access detailed analysis of Kamada’s growth prospects, along with 8 additional key investment tips for this stock.
"We are extremely pleased to announce the FDA approval of our state-of-the-art plasma collection center in Houston," said Amir London, Chief Executive Officer of Kamada.
The Houston center is structured to collect both normal source plasma and specialty plasma, such as Anti-Rabies and Anti-D. The company claims the facility is anticipated to be one of the largest sites for specialty plasma collection in the United States.
Following the FDA approval, Kamada plans to seek subsequent inspection and approval from the European Medicines Agency for the Houston location.
The Houston center joins Kamada’s two other Texas-based plasma collection sites in San Antonio and Beaumont. The San Antonio center, which opened in March 2025, is also projected to generate $8 million to $10 million in annual revenue at full capacity.
Kamada is a global biopharmaceutical company that specializes in plasma-derived therapies for rare and serious conditions. The company’s portfolio includes six FDA-approved specialty plasma-derived products. Financial metrics from InvestingPro show the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 3.3, indicating robust operational efficiency. Investors can access comprehensive analysis and valuation metrics through InvestingPro’s detailed research reports, available for over 1,400 US stocks including Kamada.
In other recent news, Kamada Ltd. reported its first-quarter financial results for 2025, showing a 17% increase in revenue to $44.0 million compared to the previous year. Earnings per share rose to $0.07, up from $0.04 in the same quarter last year. These figures met the expectations set by Benchmark analysts, who had projected $43.5 million in revenue and $0.07 EPS. The revenue growth was largely attributed to a 19% increase in proprietary product sales, with notable contributions from Glassia and Kamrab, especially in international markets. Additionally, Kamada experienced a rise in royalty income from Glassia and increased sales of Varizig in North America. In light of these developments, Benchmark analysts maintained their Buy rating for Kamada, with a price target of $15.00.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.